Dr. Selig is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
75 Francis St
Boston, MA 02115Phone+1 617-525-6841- Is this information wrong?
Education & Training
- University of Colorado School of Medicine Anschutz Medical CampusClass of 2007
- Brigham and Women's HospitalResidency, Internal Medicine
Certifications & Licensure
- MA State Medical License 2007 - 2012
Publications & Presentations
PubMed
- 2 citationsRBL2 bi-allelic truncating variants cause severe motor and cognitive impairment without evidence for abnormalities in DNA methylation or telomeric function.Nadra Samra, Shir Toubiana, Hilde Yttervik, Aya Tzur-Gilat, Ilham Morani, Chen Itzkovich, Liran Giladi, Kamal Abu Jabal, John Z. Cao, Lucy A. Godley, Adi Mory, Hagit B...> ;Journal of Human Genetics. 2021 May 13
- 2 citationsEpigenetic Characteristics of Human Subtelomeres Vary in Cells Utilizing the Alternative Lengthening of Telomeres (ALT) Pathway.Shir Toubiana, Aya Tzur-Gilat, Sara Selig> ;Life. 2021 Mar 26
- 12 citationsThe Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019).Vivian Chua, Jane Mattei, Anna Han, Lauren Johnston, Kyleigh LiPira, Sara Selig, Richard D. Carvajal, Andrew E. Aplin, Sapna Pradyuman Patel> ;Clinical Cancer Research. 2021 Jan 1
- Join now to see all
Press Mentions
- Immunocore Announces FDA Approval of KIMMTRAK® (Tebentafusp-Tebn) for the Treatment of Unresectable or Metastatic Uveal MelanomaJanuary 27th, 2022
- Melanoma Research Foundation Launches Historic Patient-Reported Ocular Melanoma RegistryMay 10th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: